GW Pharma Bets On Europe For Epidiolex Growth
Sales Of Cannabinoid Steadily Rise In US
The company expects the first ever plant-derived cannabinoid to be authorized in Europe to benefit from having already been used by over 1,100 patients with hard-to-treat forms of epilepsy in early access programs.
